KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

ClearPoint Neuro (CLPT) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for ClearPoint Neuro (CLPT) over the last 13 years, with Q3 2025 value amounting to 59.54%.

  • ClearPoint Neuro's EBITDA Margin rose 39600.0% to 59.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 66.31%, marking a year-over-year decrease of 45200.0%. This contributed to the annual value of 62.91% for FY2024, which is 308000.0% up from last year.
  • Per ClearPoint Neuro's latest filing, its EBITDA Margin stood at 59.54% for Q3 2025, which was up 39600.0% from 61.64% recorded in Q2 2025.
  • ClearPoint Neuro's 5-year EBITDA Margin high stood at 54.12% for Q1 2021, and its period low was 119.85% during Q2 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 73.75% (2022), whereas its average is 77.49%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first tumbled by -470300bps in 2021, then skyrocketed by 597300bps in 2024.
  • Quarter analysis of 5 years shows ClearPoint Neuro's EBITDA Margin stood at 92.99% in 2021, then rose by 7bps to 86.37% in 2022, then increased by 20bps to 69.1% in 2023, then fell by -5bps to 72.68% in 2024, then grew by 18bps to 59.54% in 2025.
  • Its EBITDA Margin was 59.54% in Q3 2025, compared to 61.64% in Q2 2025 and 72.63% in Q1 2025.